Vertex Average Equity vs Earnings before Tax Analysis
VRTX Stock | USD 417.51 0.19 0.05% |
Trend analysis of Vertex Pharmaceuticals balance sheet accounts such as Total Assets of 23.9 B, Short Long Term Debt Total of 848.8 M, Other Current Liabilities of 3.1 B or Total Current Liabilities of 3.7 B provides information on Vertex Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Vertex Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Vertex Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Vertex |
About Vertex Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Vertex Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Vertex Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Vertex Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Vertex currently owns. An asset can also be divided into two categories, current and non-current.
Vertex Pharmaceuticals Balance Sheet Chart
Vertex Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Vertex Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Vertex Pharmaceuticals' Cash And Short Term Investments are fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 23.9 B in 2024, despite the fact that Net Debt is likely to grow to (9.1 B). Add Fundamental
Total Assets
Total assets refers to the total amount of Vertex Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vertex Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Vertex Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Vertex Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Vertex Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 798.2 M in 2024, whereas Discontinued Operations is likely to drop (861.8 K) in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 6.7B | 7.9B | 8.6B | 9.0B | Total Revenue | 7.6B | 8.9B | 9.8B | 10.3B |
Vertex Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Vertex Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vertex Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 8.3B | 11.8B | 13.4B | 18.2B | 22.7B | 23.9B | |
Short Long Term Debt Total | 577.4M | 581.5M | 556.7M | 561M | 808.4M | 848.8M | |
Other Current Liab | 1.0B | 1.2B | 1.5B | 1.9B | 2.9B | 3.1B | |
Total Current Liabilities | 1.2B | 1.6B | 1.9B | 2.4B | 3.5B | 3.7B | |
Total Stockholder Equity | 6.1B | 8.7B | 10.1B | 13.9B | 17.6B | 18.5B | |
Property Plant And Equipment Net | 745.1M | 958.5M | 1.1B | 1.1B | 1.5B | 1.5B | |
Net Debt | (2.5B) | (5.4B) | (6.2B) | (9.9B) | (9.6B) | (9.1B) | |
Retained Earnings | (1.9B) | 858.7M | 3.2B | 6.5B | 10.1B | 10.6B | |
Cash | 3.1B | 6.0B | 6.8B | 10.5B | 10.4B | 10.9B | |
Non Current Assets Total | 3.7B | 3.9B | 4.4B | 5.5B | 8.6B | 9.0B | |
Non Currrent Assets Other | 326.9M | 662.5M | 901.1M | 1.3B | 796.7M | 836.5M | |
Cash And Short Term Investments | 3.8B | 6.7B | 7.5B | 10.8B | 11.2B | 11.8B | |
Common Stock Shares Outstanding | 260.7M | 263.4M | 259.9M | 259.1M | 260.5M | 153.1M | |
Liabilities And Stockholders Equity | 8.3B | 11.8B | 13.4B | 18.2B | 22.7B | 23.9B | |
Non Current Liabilities Total | 1.0B | 1.5B | 1.5B | 1.8B | 1.6B | 1.7B | |
Other Current Assets | 213.5M | 308.4M | 187.2M | 74.4M | 620.5M | 651.5M | |
Other Stockholder Equity | 7.9B | 7.9B | 6.9B | 7.4B | 7.4B | 7.8B | |
Total Liab | 2.2B | 3.1B | 3.3B | 4.2B | 5.1B | 5.4B | |
Total Current Assets | 4.6B | 7.8B | 9.0B | 12.7B | 14.1B | 14.9B | |
Short Term Debt | 30.3M | 42.4M | 46.9M | 89.4M | 83.7M | 51.0M | |
Accounts Payable | 87.6M | 155.1M | 195M | 303.9M | 364.9M | 383.1M | |
Property Plant And Equipment Gross | 745.1M | 958.5M | 2.3B | 2.5B | 2.6B | 2.8B | |
Accumulated Other Comprehensive Income | (2.0M) | (68.5M) | 15.9M | 800K | (14.3M) | (13.6M) | |
Net Receivables | 633.5M | 885.4M | 1.1B | 1.4B | 1.6B | 1.6B | |
Common Stock Total Equity | 2.6M | 2.6M | 2.5M | 2.6M | 3.0M | 1.9M | |
Common Stock | 2.6M | 2.6M | 2.5M | 2.6M | 3.0M | 2.0M | |
Other Assets | 1.2B | 587.0M | 986.9M | 1.4B | 1.6B | 1.7B | |
Short Term Investments | 699.0M | 670.7M | 729.9M | 274.5M | 849.2M | 579.6M | |
Property Plant Equipment | 833.3M | 958.5M | 1.1B | 1.5B | 1.7B | 1.8B | |
Other Liab | 275.5M | 923.4M | 902.2M | 685.8M | 788.7M | 828.1M | |
Current Deferred Revenue | 62.3M | 191.5M | 171.7M | 159.6M | 170.3M | 118.8M | |
Inventory | 167.5M | 280.8M | 353.1M | 460.6M | 738.8M | 775.7M | |
Net Tangible Assets | 4.7B | 7.3B | 8.7B | 12.2B | 14.1B | 14.8B | |
Retained Earnings Total Equity | (1.9B) | 858.7M | 3.2B | 6.5B | 7.5B | 7.9B | |
Long Term Debt Total | 583.9M | 581.6M | 538.6M | 539.0M | 619.9M | 632.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GOOG | Alphabet Class C | |
S | SentinelOne |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.89 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.